Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RV4P
|
|||
| Former ID |
DNCL002529
|
|||
| Drug Name |
Daratumumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Approved | [1], [2], [3] | |
| Company |
Genmab Princeton, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | . | [4] |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| WikiPathways | Oxytocin signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395). | |||
| REF 2 | ClinicalTrials.gov (NCT02252172) Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.